Bristol Myers Squibb Co. acquired Mirati Therapeutics, Inc. to expand its commercial portfolio by including KRAZATI, a critical drug for the treatment of adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Furthermore, the business aims to strengthen its pipeline of oncology products and are excellent candidate for both single-agent development and combination approaches to guarantee that patients around the world may benefit from Mirati's array of cutting-edge medications.
Celleron Therapeutics Ltd. partnered with Roche to receive rights to the clinical development, and commercialization of cancer drugs, Emactuzumab, an investigational monoclonal antibody that targets and reduces macrophages in tumor tissue.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5349
Published Date: Oct 30, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising cases of cancer across the globe and the growing research & development activities for the development of advanced drugs are the major factors driving the growth of the market.
The market size of HDAC (Histone Deacetylase) Inhibitors is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Novartis AG, Midatech Pharma PLC, REGENACY PHARMACEUTICALS, INC., Syndax Pharmaceuticals Inc., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., Cetya Therapeutics Inc., Tokyo Chemical Industry Co. Ltd., AstraZeneca Plc.
The oral HDAC inhibitors segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.